No significant differences were observed in ANA presence between total COVID19 patients and controls, or between COVID19 patients with favorable (n=6/32; 19%) and unfavorable disease course (n=7/33; 21%) (p= 0.804; Table 1A). This evidence concerns the gene BTG3 and COVID-19.